Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAY1753011 + furosemide is a combination of a novel, dual-acting vasopressin receptor antagonist (BAY1753011) and the loop diuretic furosemide. **BAY1753011** targets both V1a and V2 vasopressin receptors, blocking vasopressin-induced water retention and vasoconstriction, as well as exerting antifibrotic and antihypertrophic effects. **Furosemide** is a potent loop diuretic, commonly used for the treatment of hypertension and edema associated with conditions such as congestive heart failure, cirrhosis, and renal disease, acting through inhibition of sodium-potassium-chloride cotransport in the nephron. The combination aims for **decongestion and vascular protection in heart failure** while limiting the activation of the renin-angiotensin system, exploiting both diuretic and vasopressin antagonism mechanisms[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BAY1753011 + furosemide.